Current Microsatellite Stability Results in Colon Cancer

Launched by TURKISH SOCIETY OF COLON AND RECTAL SURGERY · May 6, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Current Microsatellite Stability Results in Colon Cancer," is focused on understanding a specific DNA repair issue called mismatch repair deficiency (dMMR) in colon cancer patients in Turkey. The researchers aim to find out how common dMMR is, how it varies based on the tumor's location in the colon, and how it relates to patient outcomes after treatment. They will also examine how often the status of a related condition called microsatellite instability (MSI) is reported in biopsy results before surgery. The goal is to gather information that could help improve treatment options, especially for those who might benefit from immunotherapy, which is a type of treatment that helps the immune system fight cancer.

To be eligible for this study, participants must have had surgery for colon adenocarcinoma between June 1, 2025, and May 31, 2026, at a hospital that performs a significant number of colon cancer surgeries each year. Their medical records will be reviewed to collect important information about their cancer, including tumor location and biopsy results. It's important to note that this study will not involve any new treatments; instead, it will use existing medical records to gather data. The results will be shared at scientific meetings and published in medical journals to help enhance understanding and care for colon cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who have undergone curative-intent surgery for colon adenocarcinoma between June 1, 2025, and May 31, 2026 Surgery performed at a center with \>30 colon cancer surgeries per year Availability of MMR protein immunohistochemistry (IHC) and/or MSI test results from resection specimen and/or preoperative endoscopic biopsy Signed informed consent for participation and data collection
• Exclusion Criteria:
• • Non-adenocarcinoma malignancies of the colon (e.g., neuroendocrine tumors, lymphomas) Rectal cancers (defined as tumors within 15 cm of the anal verge on endoscopy or MRI) Incomplete medical or pathological records preventing classification of MMR status